8:50 am Chair’s Opening Remarks
Widening the Therapeutic Window With a Varied Approach to Cell Engagement That Involves the Entire Immune System
9:00 am A Multipronged Approach to Activating the Power of the Innate Immune System: Innate Cell Engagers Monotherapy or in Combination with Other Agents
Synopsis
- Demonstrating the growing body of evidence that innate cell engagement provides new therapeutic options for patients in need
- Sharing new data of Affimed’s Innate Cell Engagers (ICE® molecules) AFM13, AFM24 and AFM28
- Outlining the three-pronged approach with the ICE® as monotherapy, or in combination with NK cell products or checkpoint inhibitors
9:30 am Panel Discussion: Leveraging Innate & Adaptive Systems to Open the Therapeutic Window with Novel, Rational Combinations
Synopsis
- Which approach holds more potential: doubling down on T-Cell activity through combination therapy with PD-1/PD-L1 (for example), or harnessing alternative cell types such as innate immune cell engagers and gamma delta T-Cells?
- Evaluate the key risks and opportunities presented by each of these approaches
- Consider the limitations of these areas
- Discuss the ideal sequencing of agents to form a sustained response
- What are the key risks and opportunities that are presented by each of these approaches?
- What are the limitations of these areas?
- What is the ideal sequencing of agents to induce a sustained response?
10:00 am
Morning Refreshments & Speed Networking Break
Presentation from Beacon Intelligence Bispecifics Team
Inducing a Safer & More Sustained Immune Gamma Delta Response by Targeting Innate Immune Cell Engagers & γδ T-Cells
11:00 am Gamma-delta T-cells: Novel approaches to genetic engineering and cell-type specific therapeutic applications
11:30 am Targeting Tumor Macrophages to Change the Tumor Microenvironment from Immunosuppressive to Immune Active
Synopsis
- Identifying synergy with checkpoint inhibitors, radiation and chemotherapy
- Review current progress in the field
12:00 pm QPCTL: A Small Molecule Drug Target Modulating the Innate Immune Response
Synopsis
- Hear how Scenic is developing a small molecule therapeutic in the oncology space
- Understand how QPCTL modulates 2 key innate immune pathways, including CD47/SIRPa
- Explore how QPCTL is a well understood MoA and extensively validated
12:30 pm
Lunch Break
1:30 pm Expanding Vd2 In Vivo For Immunotherapy
Synopsis
- Hear about the development of a proprietary platform to expand vd2 T cells
- Understand how expanded cells are activated and target multiple cancer cell types
- Assess activated vd2 spare healthy cells
2:00 pm Cancer Immunotherapy Using TGF-Beta Conditioned Gamma Delta T Cells
Synopsis
- Explore how TGF-Beta enhances the yield and viability of expanded gamma delta T-cells
- Discuss how gamma delta cells achieve more efficient tumor cell killing and cytokine release and resist suppression by TGF-Beta or PGE2
- Understand how gamma delta cells mediate enhanced anti-tumor and anti-leukemic activity
Learnings From Treg & CAR Successes
2:30 pm The Present & Future of Treg Cell Therapy
Synopsis
- Gain an overview of Treg biology and how Tregs could theoretically be harnessed to improve Cell Engager therapies
- Identify the key areas where Tregs are least understood